Functional validation experiments confirmed that tumor-conditioned dendritic cells upregulate ICOSL expression and promote CD8+ T-cell activation through the ICOS–ICOSL axis, as evidenced by increased CD69 and CD25 expression. This evidence concerns the gene CD8A and neoplasm.